Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Relay Therapeutics (RLAY) over the last 5 years, with Q3 2025 value amounting to $1.1 million.

  • Relay Therapeutics' Other Accumulated Expenses fell 2050.15% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 2050.15%. This contributed to the annual value of $2.0 million for FY2024, which is 6528.24% up from last year.
  • As of Q3 2025, Relay Therapeutics' Other Accumulated Expenses stood at $1.1 million, which was down 2050.15% from $609000.0 recorded in Q2 2025.
  • Relay Therapeutics' 5-year Other Accumulated Expenses high stood at $26.9 million for Q3 2022, and its period low was $396000.0 during Q4 2021.
  • In the last 5 years, Relay Therapeutics' Other Accumulated Expenses had a median value of $1.7 million in 2024 and averaged $9.3 million.
  • As far as peak fluctuations go, Relay Therapeutics' Other Accumulated Expenses soared by 650404.04% in 2022, and later plummeted by 9696.0% in 2024.
  • Relay Therapeutics' Other Accumulated Expenses (Quarter) stood at $396000.0 in 2021, then skyrocketed by 6504.04% to $26.2 million in 2022, then tumbled by 95.4% to $1.2 million in 2023, then surged by 65.28% to $2.0 million in 2024, then crashed by 45.83% to $1.1 million in 2025.
  • Its Other Accumulated Expenses stands at $1.1 million for Q3 2025, versus $609000.0 for Q2 2025 and $1.7 million for Q1 2025.